Roundup: harrison.ai launches joint venture with Sonic Healthcare and other partnership briefs
harrison.ai, Sonic Healthcare launch pathology AI venture
AI healthcare startup harrison.ai and ASX-listed diagnostic service provider Sonic Healthcare have formed a joint venture called franklin.ai.
Based on a media release, Franklin.ai will develop and provide pathologists with AI-powered aids to improve diagnostic accuracy and efficiency.
The venture will be led by former COO of harrison.ai, Stephen Ruffels. As CEO, he will oversee a team of more than 70 specialist engineers, data scientists and clinical experts by the end of 2023.
Other key employees for the venture include former ResMed director Peter Dassos as general manager and head of talent Celeste Kocabay, who previously worked for Atlassian and Investible.
“We have spent months building the right team to work with pathologists to develop AI-powered tools that will enhance their vital role at the center,” says Ruffels. of the health care system”.
annalise.ai book important appointments before entering the US
AI radiology provider annalise.ai has made two key appointments to support its expansion into the US market.
In a press statement, the company announced that it has appointed Lakshmi Gudapakkam as CEO and Dr Rick Abramson as CEO. Both newly hired executives are expected to help accelerate annalise.ai’s global expansion and secure more partnerships with healthcare providers, home technology developments and regulatory bodies around the world.
Gudapakkam previously worked with US-based Quest Diagnostics as Vice President and General Manager for the US East region. He has held senior global technology and business leadership roles for more than two decades at GE Healthcare and Philips Healthcare.
Meanwhile, Dr. Abramson, an American physician and board-certified radiologist, is the former Corporate Vice President of Radiology Services at HCA Healthcare.
Their appointments also come as annalize.ai has received a 510(k) clearance from the US Food and Drug Administration for its flagship product, Annalize Enterprise CXR. The AI chest X-ray tool has also been approved for use in Australia, the UK, Europe, Southeast Asia and New Zealand.
ResApp extends license agreement with Medgate
ASX-listed digital health company ResApp Health has renewed its commercial licensing agreement with telemedicine provider Medgate to use its smartphone-based respiratory diagnostic test. surname.
The companies first entered into a licensing agreement to use ResAppDx on the Medgate telehealth platform last August. The app-based test uses machine learning to analyze cough sounds and diagnose respiratory illnesses.
As revealed by a company, the extension will be extended for another 12 months.
Medgate CEO Dr Andy Fischer shared that over the past year, they have found more evidence of the benefits of ResAppDx for doctors and their patients. He added: “We look forward to expanding the use of ResAppDx to realize these benefits for our patients.
Medgate also intends to expand the use of ResAppDx in the “additional journey of the patient” in its telemedicine services and bring the technology to its platform in Germany by 2023.
Volpara deploys its AI breast imaging solutions in RadNet diagnostic centers
New Zealand-based medical technology developer Volpara Health Technologies has contracted for use with RadNet, an imaging service provider in the United States.
Set for an initial period of 42 months, their contract was to deploy Volpara Analytics and Volpara Risk Pathways software across 353 RadNet imaging centers in seven US states.
Volpara Analytics manages the quality of mammograms while Volpara Risk Pathways provides screening for patients at high risk of developing breast cancer.
According to a company disclosure, the rollout will be made within the next year.
